Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
Combined drug therapy with cholestyramine and compactin was found to be extremely effective against heterozygous cases of familial hypercholesterolemia. With a single drug regimen, compactin at a dosage of 15 mg/day produced a cholesterol reduction of 23% (70 mg/dl) in cases of combined hyperlipidemia, while twice the dosage (30 mg/day) was needed to produce a comparable effect with heterozygous familial hypercholesterolemia. When compaction was combined with cholestyramine (in a 4 g dose three times a day), the cholesterol-lowering effect of compactin was strongly improved with heterozygous familial hypercholesterolemia; half the dosage of compactin was enough to produce the additive effect compared with the effect produced by each single drug regimen.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000031:analogs & derivatives*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008055:Lipids; D009281:Naphthalenes; D002792:Cholestyramine Resin; C012258:mevastatin; D008148:Lovastatin